<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02184273</url>
  </required_header>
  <id_info>
    <org_study_id>1093.18</org_study_id>
    <nct_id>NCT02184273</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Nolotil i.v. vs. Placebo i.v. in the Prevention of Postoperative Pain in Children Undergoing Minor Surgery</brief_title>
  <official_title>Randomized, Double Blind, Comparative Trial of the Efficacy and Tolerability of Nolotil i.v. vs. Placebo i.v. in the Prevention of Postoperative Pain in Children of 6 and 11 Years Old Undergoing Minor Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess the analgesic efficacy in the prevention of postoperative pain in children&#xD;
      undergoing minor surgery (herniorraphy, tonsillectomy) and to assess the tolerability of&#xD;
      Metamizol in this group of patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of children requiring rescue medication</measure>
    <time_frame>up to 4 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from drug administration, end of surgery and first patient's awake to the administration of rescue medication</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of children who require rescue medication</measure>
    <time_frame>up to 2 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the pain intensity by the patient by means of a Visual Analogue Scale (VAS)</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the pain intensity by the patient by means of a four points Verbal Rating Scale (VRS)</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the state of the patient by the guardian by means of the Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) test</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the partial efficacy by the investigator by means of a four points VRS</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the total efficacy by the investigator by means of a four points VRS</measure>
    <time_frame>after 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events (AE)</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of withdrawals due to AEs</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the total tolerability of the assigned treatment by the investigator by means of a four points VRS</measure>
    <time_frame>after 4 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Magnesium metamizol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium metamizol</intervention_name>
    <arm_group_label>Magnesium metamizol</arm_group_label>
    <other_name>Nolotil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children of either sex between 6 and 11 years of age&#xD;
&#xD;
          -  Patients undergoing routine inguinal hernia repair or tonsillectomy&#xD;
&#xD;
          -  Written informed consents by the guardian, according to the guidelines of Good&#xD;
             Clinical Practice and current legislation&#xD;
&#xD;
          -  The ability of the patient to understand and carry out the visual analogue scale&#xD;
             assessments&#xD;
&#xD;
          -  Patients with a physical status American Society of Anesthesiologist I or II class&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The use of any drug with analgesic properties in the 24 hours prior to the&#xD;
             administration of the study drug&#xD;
&#xD;
          -  Surgery with a foreseen duration over 60 minutes&#xD;
&#xD;
          -  Patients with a nutritional index of less than 90 or greater than 120&#xD;
&#xD;
          -  Patients with a body mass index which was not between the 3rd centile and the 97th&#xD;
             centile for age&#xD;
&#xD;
          -  Patients with any illness or malformation (except hernia) which, in the doctor's&#xD;
             opinion, contraindicated the use of metamizol (aplastic anemia, agranulocytosis of a&#xD;
             toxicological etiology, severe renal disease, etc.)&#xD;
&#xD;
          -  Patients who have received in the previous 7 days or need currently anticoagulant&#xD;
             treatment&#xD;
&#xD;
          -  Significant allergy or known hypersensitivity to metamizol, its excipients and/or to&#xD;
             other nonsteroidal antiinflammatory drugs&#xD;
&#xD;
          -  Patients in whom the anesthetic regimen required by the protocol cannot be used&#xD;
&#xD;
          -  Patients who have participated in another clinical trial in the past four weeks or are&#xD;
             currently participating in another clinical trial&#xD;
&#xD;
          -  Patients with any psychological disturbance which, in the investigator's opinion makes&#xD;
             the patient unsuitable for inclusion in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1093/1093.18_U05-1666.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 8, 2014</study_first_submitted>
  <study_first_submitted_qc>July 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>July 9, 2014</last_update_submitted>
  <last_update_submitted_qc>July 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dipyrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

